Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fluoroquinolones To Get “Better” But Not Necessarily Stronger Warning On Nerve Damage

This article was originally published in The Pink Sheet Daily

Executive Summary

Risk of peripheral neuropathy is already in labeling and FDA doesn’t want to require a black box, illustrating the agency’s ongoing challenge to fully communicate risks without unduly limiting access or use.

You may also be interested in...



Fluoroquinolones Get New Safety Labeling, But Not A REMS

Risk of disabling, potentially permanent serious side effects that can occur together will be added to Cipro, Levaquin labels along with limitation against use for some self-limiting conditions unless there are no alternative treatments.

FDA Adverse Event Data Clouds Potential Fluoroquinolone Label Changes

Advisory committee unsure how to describe fluoroquinolone-associated disability in labeling.

Fluoroquinolones: Is Another FDA Safety Step Needed?

Joint advisory committee meeting will discuss post-marketing safety data, including adverse events across organ systems.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel